Opinion|Videos|October 4, 2024
Urgency to Treat in Lupus Nephritis: Goals of Therapy and Early Diagnosis Strategies
Panelists discuss the goals of therapy for lupus nephritis (LN), emphasizing the urgency of treatment to prevent renal flares and the consequences of untreated LN, as well as strategies for increasing early diagnosis and screening in patients with systemic lupus erythematosus.
Episodes in this series
- What are the goals of therapy for patients with lupus nephritis (LN)? What does urgency to treat mean in LN?
- What are the consequences of untreated LN or renal flares?
Objective: Examine strategies for early diagnosis/screening, updated treatment guidelines, and treatment and payer considerations to optimize lupus nephritis management and address patient access challenges.
- What strategies have you found effective in increasing the screening and early diagnosis of LN in patients with either diagnosed or suspected systemic lupus erythematosus (SLE)?
- Who are these patients who should be screened for LN?
How can payers support screening for LN in patients with SLE?
Related to this article
North Carolina experts discussed CLL, breast cancer, and myeloma treatments and how to expand access to complex cancer care beyond academic centers.
The IRA's Medicare out-of-pocket cap is easing costs for patients with cancer, but community oncology leaders warn price cuts are straining practices.
A follicular lymphoma survivor shares axi-cel CAR T-cell therapy highs, experiences with severe CRS and neurotoxicity, and why access to care and clinical trials improve quality of life.
Biomarker testing, referrals, screening, treatment access, and clinical trial barriers were examined during this recent IVBM.
Oncologists say advances in testing and treatment are outpacing staffing, pay, and access.
Home NB-UVB phototherapy matches office results, boosts psoriasis treatment adherence, and may improve access, but long-term safety, equity, and oversight lag.
Upper-extremity synovial sarcoma required more staged surgery, while lower-extremity disease carried more complications and metastases.
In the US alone, 1.1 million individuals are living with the progressive neurodegenerative movement disorder, and 90,000 are diagnosed each year.